Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A blood and marrow transplant clinical trials network study

Blood

Volumn 119, Issue 16, 2012, Pages 3854-3860

  Levine, John E ^a   Logan, Brent R ^b   Wu, Juan ^c   Alousi, Amin M ^d   Bolaños Meade, Javier ^e   Ferrara, James L M ^a   Ho, Vincent T ^f   Weisdorf, Daniel J ^g   Paczesny, Sophie ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DENILEUKIN DIFTITOX; ELAFIN; ETANERCEPT; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; REGENERATING ISLET DERIVED 3 ALPHA; SCATTER FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 84860345135     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403063     Document Type: Article

References (15)

1. Cutler C, Antin JH. Manifestation and treatment of acute graft-versus-host-disease. In: Appelbaum F, Forman SJ, Negrin RS, Blume KG, eds. Thomas' Hematopoietic Cell Transplantation. Oxford: Blackwell Publishing Ltd; 2009:1287-1303.
2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373(9674): 1550-1561.
3. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170. (Pubitemid 46697905)
4. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonre-sponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177-4181. (Pubitemid 43726830)
5. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119- 4126. (Pubitemid 46743372)
6. Levine JE, Logan B, Wu J, et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant. 2010;16(12):1693-1699.
7. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010;115(26):5412-5417.
8. Saliba RM, Couriel DR, Giralt S, et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012;47(1): 125-131.
9. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273-278.
10. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010;2(13):13ra12.
11. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3 alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-8.
12. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood. 2009;114(3):511-517.
13. Socié G. Graft-versus-host disease: proteomics comes of age. Blood. 2009;113(2):271-272.
14. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11-e79. (Pubitemid 352777353)
15. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312. (Pubitemid 350232263)